PRESS RELEASES

RAYMEDICA® ANNOUNCESS AUTHORS FOR VOLUME IV OF THE 4-PART SERIES ON "NUCLEUS ARTHROPLASTY™ TECHNOLOGY IN SPINAL CARE"

MINNEAPOLIS- May 2, 2007 - Raymedica, the Pioneer in Nucleus Arthroplasty, announced today the Authors of its upcoming Volume IV publication in the ground-breaking Series entitled, “Nucleus Arthroplasty™ Technology in Spinal Care.” Volume IV “Emerging Technology,” will be released at the North American Spine Society (NASS) 22nd Annual Meeting being held in Austin, Texas, October 23-27, 2007.

“The invited authors offer a unique prospective on the emerging concept of Nucleus Arthroplasty and address this technology with objective integrity,” stated John J. Viscogliosi, Chairman & CEO of Raymedica. Mr. Viscogliosi, added, “The strategies, suggestions, and guidance they contribute add tremendously to the overall “value” of this educational Series.”

Volume IV, “Emerging Technology”, scheduled for release at the North American Spine Society (NASS) 22nd Annual Meeting in October, 2007, will include the following invited Authors and topics:

• Chapter 21, “Nucleus Arthroplasty Technology: Patient Selection & Procedure Demographics,” invited co-authors: Alejandro Reyes-Sanchez, MD, Mexico City, Mexico and John S. Thalgott, MD, Las Vegas, NV.

• Chapter 22, “Nucleus Arthroplasty vs. TDR – Approach/Access and Procedure,” invited co-authors: Salvador A. Brau, MD, FACS, Los Angeles, CA; Gary A. Fantini, MD FACS, New York, NY; Dr. med. univ. Rudolf Bertagnoli, Straubing, Germany, and Rick B. Delamarter, MD, Santa Monica, CA.

• Chapter 23, “Nucleus Arthroplasty: Challenges of Implant Design ,” invited lead author, Prof. Dr. Hans-Joachim Wilke, Ulm, Germany.

• Chapter 24, “Nucleus Arthroplasty: Clinical Experience,” invited lead author, Hyun W. Bae, MD, Santa Monica, CA.

• Chapter 25, “Socioeconomic Impact of Nucleus Arthroplasty Technology,” invited lead author: Alexander R. Vaccaro, MD, Philadelphia, PA.

• Chapter 26, “Biologics and Nucleus Arthroplasty Technology Applications,” invited lead author: Jeffrey C. Wang, MD, Los Angeles, CA.

• Chapter 27, “The Future of Nucleus Arthroplasty Technology,” co-authored by the Series’ Deputy Editorial Board: Reginald J. Davis, MD, FACS, Baltimore, MD; Federico P. Girardi, MD, New York, NY and Frank P. Cammisa, Jr. MD, FACS, New York, NY

Raymedica has created a website to provide access to this, and previous published volumes. Nucleusarthroplasty.com is primarily an educational website designed to provide valuable guidance to spine surgeons as they seek to provide more effective and less invasive options for the treatment of degenerative disc disease (DDD). The service is free to physicians and the general public at www.nucleusarthroplasty.com.

About Raymedica
Raymedica, based in Minneapolis, Minnesota, is the Pioneer in Nucleus Arthroplasty having developed the world’s first nucleus replacement device in 1996. Raymedica develops, manufactures and markets medical device systems designed to treat patients with degenerative disc disease that have been unresponsive to non-surgical treatment. Raymedica’s products are currently available in many countries worldwide, but are limited to investigational use only in the United States. For more information, visit the Company's website at http://www.raymedica.com.

About Viscogliosi Bros., LLC
Established by Marc R. Viscogliosi, John J. Viscogliosi and Anthony G. Viscogliosi in New York City in 1999, Viscogliosi Bros., LLC (VB) was the first venture capital/private equity and merchant banking firm dedicated to the musculoskeletal/orthopedics sector of the health care industry.
 
Today, VB is a leading independent firm with a mission to create, build and finance companies founded on innovations developed by surgeons and uniquely focused on "life changing" musculoskeletal/orthopedic technologies. VB has worldwide surgeon, industry and trade relationships and significant financial expertise in the musculoskeletal/orthopedic sector.

As principals of VB, the Viscogliosi brothers have a combined total of nearly half a century of experience analyzing and investing in the musculoskeletal/orthopedics sector, directing literally billions of dollars through the orthopedics industry.  They have pioneered innovative financial, strategic and management initiatives for nearly 150 companies in the sector, from start-up, seed and development stage all the way to exit, while helping thousands of people lead better lives through the orthopedic and spinal products marketed and sold by the companies they have assisted in developing and financing.


> Back to Press Releases

 

Viscogliosi Bros., LLC is not an investment adviser, money manager, asset manager or otherwise give investment advice.